Vertriebsvereinbarung für Zemcelpro® in Argentinien, Hongkong und Singapur bekannt gegeben

PartnershipZemcelproPositive

AI Analysis

Summary

FarmaMondo has secured distribution rights for Zemcelpro (Dorocubicel), a European Commission-approved cell therapy, in Argentina, Hong Kong, and Singapore. This partnership expands market access for the UM171-based cell therapy in additional geographic regions.

Outcome Details

Distribution agreement for Zemcelpro in Argentina, Hong Kong, and Singapore

Importance:5/10

Sentiment:

0.60

distribution agreementcell therapyinternational expansionEuropean Commission approvalhematological malignancies

Read the original article

Published by PR Newswire Clinical Trials on July 16, 2026 5:04 PM

Read Original